Emergence of multidrug-resistant Proteus mirabilis in a long-term care facility in Croatia
An increased frequency of Proteus mirabilis isolates resistant to expanded-spectrum cephalosporins was observed recently in a long-term care facility in Zagreb (Godan). The aim of this study was the molecular characterization of resistance mechanisms to new cephalosporins in P. mirabilis isolates from this nursing home.
Thirty-eight isolates collected from 2013–2015 showing reduced susceptibility to ceftazidime were investigated. Antibiotic susceptibilities were determined by broth microdilution method. Inhibitor-based tests were performed to detect extended-spectrum (ESBLs) and AmpC β-lactamases. AmpC β-lactamases were characterized by polymerase chain reaction (PCR) followed by sequencing of bla ampC genes. Quinolone resistance determinants (qnr genes) were characterized by PCR. Genotyping of the isolates was performed by repetitive element sequence (rep)-PCR and pulsed-field gel electrophoresis (PFGE).
Presence of an AmpC β-lactamase was confirmed in all isolates by combined-disk test with phenylboronic acid. All isolates were resistant to amoxicillin alone and combined with clavulanate, cefotaxime, ceftriaxone, cefoxitin, and ciprofloxacin; but susceptible to cefepime, imipenem, and meropenem. PCR followed by sequencing using primers targeting bla ampc genes revealed CMY-16 β-lactamase in all but one strain. Bla cmy-16 was carried by a non-conjugative plasmid which did not belong to any known plasmid-based replicon typing (PBRT) group. Rep-PCR identified one large clone consisting of 15 isolates, three pairs or related isolates, one triplet, and four singletons. PFGE confirmed the clonality of the isolates.
This is the first report of multidrug resistant P. mirabilis in a nursing home in Croatia. Cephalosporin resistance was due to plasmid-mediated AmpC β-lactamase CMY-16.
KeywordsCMY-16 Proteus mirabilis AmpC β-lactamases Conjugative plasmid Clonal dissemination
Compliance with ethical guidelines
Conflict of interest
B. Bedenić, N. Firis, V. Elveđi-Gašparović, M. Krilanović, K. Matanović, I. Štimac, J. Luxner, J. Vraneš, T. Meštrović, G. Zarfel and A. Grisold state that there are no conflicts of interest.
This was in vitro study which did not involve human or animal subject and the permission from the Ethical Comittee was not necessary.
- 8.Tonkic M, Mohar B, Sisko-Kraljević K, Mesko-Meglic K, Goić-Barisić I, Novak A, Kovacić A, Punda-Polić V. High prevalence and molecular characterization of extended-spectrum β-lactamase-producing Proteus mirabilis isolates in southern Croatia. J Med Microbiol. 2010;59:1185–90.CrossRefPubMedGoogle Scholar
- 9.CLSI. Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing. 21st informational supplement. Wayne, PA: CLSI; 2011, pp. M100–21.Google Scholar
- 12.Elwell S, Falkow LP. The characterization of R plasmids and the detection of plasmid-specified genes. In: Lorian V, editor. Antibiotics in Laboratory Medicine, 2nd edn. Baltimore: Williams and Wilkins; 1986. pp. 683–721.Google Scholar
- 15.Woodford N, Ward ME, Kaufmann ME, Turton J, Fagan EJ, James D, Johnson AP, Pike R, Warner M, Cheasty T, Pearson A, Harry S, Leach JB, Loughrey A, Lowes JA, Warren RE, Livermore DM. Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum β-lactamases in the UK. J Antimicrob Chemother. 2004;54:735–43.CrossRefPubMedGoogle Scholar
- 16.Pagani L, Mantengoli E, Migliavacca R, Nucleo E, Pollini S, Spalla M, Daturi R, Romero E, Rossolini GM. Multifocal detection of multidrug-resistant Pseudomonas aeruginosa producing PER-1 extended-spectrum β-lactamase in Northern Italy. J Clin microbiol. 2004;42:2523–9.CrossRefPubMedPubMedCentralGoogle Scholar
- 22.Overdevest S, Willemsen C, Elberts M, Verhulsts P, Rijnsburger J, Savelkoulnd A, Kluytmans JW. Evaluation of the DiversiLab Typing Method in a Multicenter Study. Assessing Horizontal Spread of Highly Resistant Gram-Negative Rods. J Clin Microbiol. 2011;49:3551–54.CrossRefPubMedPubMedCentralGoogle Scholar
- 23.Kaufman ME. Pulsed-Field Gel Electrophoresis. In: Woodford N, Johnsons A, editors. Molecular bacteriology. Protocols and clinical applications, 1st edn. New York: Humana Press Inc.; 1998. pp. 33–51.Google Scholar
- 26.D’Andrea MM, Literacka E, Zioga A, Giani T, Baraniak A, Fiett J, Sadowi E, Tassios T, Rossolini GM, Gniadkowski M, Miriagou V. Evolution and spread of multidrug-resistant Proteus mirabilis clone with chromosomal AmpC β-lactamase in Europe. Antimicrob Agents Chemother. 2011;55:2735–42.CrossRefPubMedPubMedCentralGoogle Scholar
- 28.Rubić Ž, Soprek S, Jelić M, Radić M, Novak A, GoićBarišić I, Tonkić M, Tambić-Andrašević A. The first detection of plasmid-mediated AmpC β-lactamase in multidrug-resistant Proteus mirabilis isolates from University Hospital Split, Croatia 24th European congress of clinical Microbiology and Infectios Diseases, Barcelona, Spain. 2014.Google Scholar
- 29.Bedenić B, Matanović K, Mekić S, Varda-Brkić D, Šeol-Martinac B. Coproduction of CTX-M-15 and CMY-2 in animal Escherichia coli isolate from Croatia 24th European congress of clinical Microbiology and Infectios Diseases, Barcelona, Spain. 2014.Google Scholar
- 30.Zujić-Atalić V, Bedenić B, Kocsis E, Mazzariol A, Sardelić S, Barišić M, Plečko V, Bošnjak Z, Mijač M, Jajić I, Vranić-Ladavac M, Cornaglia G. Diversity of carbapenemases in clinical isolates of Enterobacteriaceae in Croatia-the results of the multicenter study. Clin Microbiol Infect. 2004;20:894–903.CrossRefGoogle Scholar
- 31.Literacka E, Empel J, Baraniak A, Sadowy E, Hryniewic W, Gniadkowski M. Four variants of the Citrobacter freundii AmpC type cephalosporinase including tow novel enzymes, CMY-14 and CMY-15 in a Proteus mirabilis clone widespread in Poland. Antimicrob Agents Chemother. 2004;48:4136–43.CrossRefPubMedPubMedCentralGoogle Scholar